Clinical Trial Update: Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating WX-671 in combination with capecitabine versus capecitabine alone in first-line HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• WX-671

Snippet

Sponsor: Heidelberg Pharma AG | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED